ウパダシチニブ
↑ “Drug Approval Package: Rinvoq”. U.S. Food and Drug Administration (FDA) (2019年9月12日). 2020年4月29日閲覧。
↑ “リンヴォックについて|リンヴォック|製品情報|A-CONNECT|アッヴィ合同会社”. a-connect.abbvie.co.jp. 2021年8月22日閲覧。
↑ Blauvelt, Andrew; Teixeira, Henrique D.; Simpson, Eric L.; Costanzo, Antonio; De Bruin-Weller, Marjolein; Barbarot, Sebastien; Prajapati, Vimal H.; Lio, Peter et al. (2021-08-04). “Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial” (英語). JAMA Dermatology. doi:10.1001/jamadermatol.2021.3023. ISSN 2168-6068. PMC 8340015. PMID 34347860. https://jamanetwork.com/journals/jamadermatology/fullarticle/2782803.
↑ “アトピーに最強の経口薬ウパダシチニブ|皮膚|医療ニュース|Medical Tribune”. Medical Tribune. 2021年8月22日閲覧。
68 (12): 2867–2877. doi:10.1002/art.39801. PMC 5132116. PMID 27389975。
↑ 近藤啓文「関節リウマチ(ACRコアセット)」『日本内科学会雑誌』第91巻第9号、日本内科学会、2002年9月、2728-2737頁、doi:10.2169/naika.91.2728、ISSN 00215384、NAID 10011015138。
↑ “Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate”. Arthritis & Rheumatology 68 (12): 2857–2866. (December 2016). doi:10.1002/art.39808. PMC 5132065. PMID 27390150. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5132065/.
↑ “A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Immunomodulators or Anti-TNF Therapy - Full Text View - ClinicalTrials.